Impel NeuroPharma is a Seattle-based company developing intranasal drug treatments for central nervous system (CNS) disorders. Impel has developed a novel drug delivery platform, the POD technology, that administers drug to the deep nasal cavity to improve the brain distribution of many drugs. Impel’s proprietary (POD) device technology enables entirely new categories of drugs, including biologics, to be delivered to the central nervous system using a cost-effective, disposable, non-invasive intranasal drug delivery device.

The goal at Impel is simple: we want to develop the next generation of therapeutics for central nervous system (CNS) disorders. Patients with CNS disorders are vastly underserved by current therapeutics and we are working hard to change that. Impel has built the POD drug delivery platform to allow entire classes of molecules to reach the brain that never could before. Impel has expanded its scope to both partnership with pharmaceutical companies and the development of our own drug products compatible with the POD platform. We take a comprehensive approach to development and design considering patient comfort, regulatory approval pathways, and cost effectiveness. Treatments currently under development include therapies for migraine, Alzheimer’s disease, Parkinson’s disease, and pain relief

Show more

Employee Rating

4.1More
TypePrivate
HQSeattle, US
Founded2008
Size (employees)44 (est)+5%
Websiteimpelnp.com
Impel NeuroPharma was founded in 2008 and is headquartered in Seattle, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Impel NeuroPharma

John Hoekman

John Hoekman

Co-Founder and CSO, Co-Founder and CSO
Jon Congleton

Jon Congleton

President & CEO, President & CEO
Stephen Shrewsbury

Stephen Shrewsbury

Chief Medical Officer
Ellen Lubman

Ellen Lubman

Chief Business Officer
Lynn Gold

Lynn Gold

Senior VP of Regulatory
Michael Malafronte

Michael Malafronte

VP of Quality Assurance
Show more

Impel NeuroPharma Office Locations

Impel NeuroPharma has an office in Seattle
Seattle, (HQ)
915 E Pine St
Show all (1)
Report incorrect company information

Impel NeuroPharma Financials and Metrics

Summary Metrics

Founding Date

2008

Impel NeuroPharma total Funding

$108.1 m

Impel NeuroPharma latest funding size

$67.50 m

Time since last funding

9 days ago

Impel NeuroPharma investors

Impel NeuroPharma's latest funding round in December 2018 was reported to be $67.5 m. In total, Impel NeuroPharma has raised $108.1 m
View all funding rounds
Report incorrect company information

Impel NeuroPharma News and Updates

Impel NeuroPharma Closes $67.5 Million Series D Financing

SEATTLE, Dec. 6, 2018 /PRNewswire/ -- Impel NeuroPharma ("Impel" or the "Company"), a Seattle-based, privately-held biotechnology company focused on developing therapies for the treatment of central nervous system ("CNS") disorders with unmet medical needs, today announced that it has...
Report incorrect company information

Impel NeuroPharma Blogs

National Updated on Behavioral Emergencies Conference – 12 DEC

The Impel team will be attending and presenting at the National Updated on Behavioral Emergencies (NUBE) Conference in Las Vegas, NV on December 12th – 14th. For more information on the event, visit the event webpage here.

19th Annual Piper Jaffray Health Care Conference

Our Impel team will be attending Piper Jaffray’s 19th Annual  Health Care Conference in New York on November 27 – 29. Management teams from nearly 300 leading public and private companies in biotechnology, specialty pharmaceuticals, drug discovery, medical technology, medical diagnostics and devices…

Impel NeuroPharma Appoints Ellen A. Lubman As Chief Business Officer

SEATTLE, Nov. 7, 2018 /PRNewswire/ — Impel NeuroPharma, a Seattle-based, privately-held biotechnology company focused on developing therapies for the treatment of central nervous system (CNS) disorders with unmet medical needs, today announced the appointment of Ellen A. Lubman as Chief Business Off…

2018 Scottsdale Headache Symposium – 15 NOV

The Impel team will be attending the 2018 Scottsdale Headache Symposium in Scottsdale, AZ on 15 November. Our team will be made up of Steve Shrewsbury, CMO; Meghan Swardstrom, VP of Clinical Operations; Maria Jeleva, Associate Director of Clinical Operations; and Sutapa Ray, Business Development Man…

American Association of Pharmaceutical Scientists – 4 NOV

Impel’s Bhavin Gajera, Formulation Scientist, is presenting at the American Association of Pharmaceutical Scientists (AAPS) conference in Washington, DC on November 4th through 7th. Bhavin Gajera will be presenting a poster on Tuesday, November 6 from 1:30 – 2:30 PM on Formulation Development and Ph…

Outsourcing in Clinical Trials Pacific Northwest 2018 – 16 OCT

Our Impel team is presenting at the Outsourcing in Clinical Trials Pacific Northwest 2018 conference in Vancouver, Canada. Our CMO, Dr. Stephen Shrewbury, will be giving a keynote presentation on Home Advantage: Assessing the Pacific Northwest’s competitive landscape to underpin and sustain your com…
Show more

Impel NeuroPharma Company Life and Culture

Report incorrect company information

Impel NeuroPharma Frequently Asked Questions

  • When was Impel NeuroPharma founded?

    Impel NeuroPharma was founded in 2008.

  • Who are Impel NeuroPharma key executives?

    Impel NeuroPharma's key executives are John Hoekman, Jon Congleton and Stephen Shrewsbury.

  • How many employees does Impel NeuroPharma have?

    Impel NeuroPharma has 44 employees.

  • Who are Impel NeuroPharma competitors?

    Competitors of Impel NeuroPharma include SteadyMed Therapeutics, K2M Group and ResMed.

  • Where is Impel NeuroPharma headquarters?

    Impel NeuroPharma headquarters is located at 915 E Pine St, Seattle.

  • Where are Impel NeuroPharma offices?

    Impel NeuroPharma has an office in Seattle.

  • How many offices does Impel NeuroPharma have?

    Impel NeuroPharma has 1 office.